Translational Research
Volume 155, Issue 5 , Pages 220-227 , May 2010

Combination drug–diet therapies for dyslipidemia

  • Todd C. Rideout

      Affiliations

    • Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba, Winnipeg, Manitoba, Canada
    • Department of Human Nutritional Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
    • Corresponding Author InformationReprint requests: Todd C. Rideout, PhD, Department of Human Nutritional Sciences, University of Manitoba, 196 Innovation Drive, Winnipeg, Manitoba, Canada R3T 6C5.
    • ,
  • Scott V. Harding

      Affiliations

    • Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba, Winnipeg, Manitoba, Canada
    • Department of Human Nutritional Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
    • ,
  • Christopher P.F. Marinangeli

      Affiliations

    • Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba, Winnipeg, Manitoba, Canada
    • ,
  • Peter J.H. Jones

      Affiliations

    • Department of Food Science, University of Manitoba, Winnipeg, Manitoba, Canada

Received 30 October 2009 ,Revised 22 December 2009 ,Accepted 23 December 2009.

References 

  1. Teoh H, Mendelsohn AA, Goodman SG, et al. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease. Am J Cardiol. 2009;104:798–804
  2. Avisar I, Brook JG, Wolfovitz E. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia. Eur J Intern Med. 2008;19:203–208
  3. Connor WE. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;359:530
  4. Rideout TC, Yuan Z, Bakovic M, et al. Guar gum consumption increases hepatic nuclear SREBP2 and LDL receptor expression in pigs fed an atherogenic diet. J Nutr. 2007;137:568–572
  5. Calpe-Berdiel L, Escola-Gil JC, Ribas V, Navarro-Sastre A, Garces-Garces J, Blanco-Vaca F. Changes in intestinal and liver global gene expression in response to a phytosterol-enriched diet. Atherosclerosis. 2005;181:75–85
  6. Farmer JA. Nicotinic acid: a new look at an old drug. Curr Atheroscler Rep. 2009;11:87–92
  7. Collins N, Tighe AP, Brunton SA, Kris-Etherton PM. Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective. J Am Coll Nutr. 2008;27:659–666
  8. Wierzbicki AS. Newer, lower, better? Lipid drugs and cardiovascular disease—the continuing story. Int J Clin Pract. 2007;61:1064–1067
  9. Reaume KT, Erickson SR, Dorsch MP, et al. Effects of cerivastatin withdrawal on statin persistence. Ann Pharmacother. 2008;42:956–961
  10. Schneeweiss S, Patrick AR, Maclure M, Dormuth CR, Glynn RJ. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation. 2007;115:2128–2135
  11. Steg PG, Verdier JC, Carre F, et al. A randomised trial of three counselling strategies for lifestyle changes in patients with hypercholesterolemia treated with ezetimibe on top of statin therapy (TWICE). Arch Cardiovasc Dis. 2008;101:723–735
  12. Jenkins DJ, Kendall CW, Faulkner D, et al. A dietary portfolio approach to cholesterol reduction: combined effects of plant sterols, vegetable proteins, and viscous fibers in hypercholesterolemia. Metabolism. 2002;51:1596–1604
  13. Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA. 2003;290:502–510
  14. Denke MA. Reviewing your investment strategy: where does diet fit in your personal portfolio. Am J Clin Nutr. 2005;81:339–340
  15. Hall WL, Vafeiadou K, Hallund J, et al. Soy-isoflavone-enriched foods and markers of lipid and glucose metabolism in postmenopausal women: interactions with genotype and equol production. Am J Clin Nutr. 2006;83:592–600
  16. Donnelly LA, Palmer CN, Whitley AL, et al. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenet Genomics. 2008;18:279–287
  17. Jakulj L, Trip MD, Sudhop T, von Bergmann K, Kastelein JJ, Vissers MN. Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: effects on plasma lipid levels. J Lipid Res. 2005;46:2692–2698
  18. Sanchez-Muniz FJ, Maki KC, Schaefer EJ, Ordovas JM. Serum lipid and antioxidant responses in hypercholesterolemic men and women receiving plant sterol esters vary by apolipoprotein E genotype. J Nutr. 2009;139:13–19
  19. Mega JL, Morrow DA, Brown A, Cannon CP, Sabatine MS. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol. 2009;29:1310–1315
  20. Hubacek JA, Adamkova V, Prusikova M, Snejdrlova M, Hirschfeldova K, Lanska V, et al. Impact of apolipoprotein A5 variants on statin treatment efficacy. Pharmacogenomics. 2009;10:945–950
  21. Zhao HL, Houweling AH, Vanstone CA, et al. Genetic variation in ABC G5/G8 and NPC1L1 impact cholesterol response to plant sterols in hypercholesterolemic men. Lipids. 2008;43:1155–1164
  22. Barcelos AL, Chies R, Almeida SE, et al. Association of CYP7A1 -278A>C polymorphism and the response of plasma triglyceride after dietary intervention in dyslipidemic patients. Braz J Med Biol Res. 2009;42:487–493
  23. Kuo PT, Hayase K, Kostis JB, Moreyra AE. Use of combined diet and colestipol in long-term (7–7 1/2 years) treatment of patients with type II hyperlipoproteinemia. Circulation. 1979;59:199–211
  24. Abumweis SS, Barake RI, Jones P. Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. Food Nutr Res. 2008;52
  25. Kapur NK, Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag. 2008;4:341–353
  26. Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29:1220–1226
  27. de Jong A, Plat J, Lutjohann D, Mensink RP. Effects of long-term plant sterol or stanol ester consumption on lipid and lipoprotein metabolism in subjects on statin treatment. Br J Nutr. 2008;100:937–941
  28. Plat J, Brufau G, Dallinga-Thie GM, Dasselaar M, Mensink RP. A plant stanol yogurt drink alone or combined with a low-dose statin lowers serum triacylglycerol and non-HDL cholesterol in metabolic syndrome patients. J Nutr. 2009;139:1143–1149
  29. Gylling H, Miettinen TA. LDL cholesterol lowering by bile acid malabsorption during inhibited synthesis and absorption of cholesterol in hypercholesterolemic coronary subjects. Nutr Metab Cardiovasc Dis. 2002;12:19–23
  30. Jones PJ, Raeini-Sarjaz M, Ntanios FY, Vanstone CA, Feng JY, Parsons WE. Modulation of plasma lipid levels and cholesterol kinetics by phytosterol versus phytostanol esters. J Lipid Res. 2000;41:697–705
  31. AbuMweis SS, Vanstone CA, Lichtenstein AH, Jones PJ. Plant sterol consumption frequency affects plasma lipid levels and cholesterol kinetics in humans. Eur J Clin Nutr. 2009;63:747–755
  32. Vanstone CA, Raeini-Sarjaz M, Parsons WE, Jones PJ. Unesterified plant sterols and stanols lower LDL-cholesterol concentrations equivalently in hypercholesterolemic persons. Am J Clin Nutr. 2002;76:1272–1278
  33. Castro Cabezas M, de Vries JH, Van Oostrom AJ, Iestra J, van Staveren WA. Effects of a stanol-enriched diet on plasma cholesterol and triglycerides in patients treated with statins. J Am Diet Assoc. 2006;106:1564–1569
  34. Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol. 2000;86:46–52
  35. Miettinen TA, Gylling H. The effects of statins and sitosterols: benefit or not?. Curr Atheroscler Rep. 2009;11:23–27
  36. van Himbergen TM, Matthan NR, Resteghini NA, et al. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res. 2009;50:730–739
  37. Helske S, Miettinen T, Gylling H, et al. Accumulation of cholesterol precursors and plant sterols in human stenotic aortic valves. J Lipid Res. 2008;49:1511–1518
  38. Kidambi S, Patel SB. Sitosterolaemia: pathophysiology, clinical presentation and laboratory diagnosis. J Clin Pathol. 2008;61:588–594
  39. Shamliyan TA, Jacobs DR, Raatz SK, Nordstrom DL, Keenan JM. Are your patients with risk of CVD getting the viscous soluble fiber they need?. J Fam Pract. 2006;55:761–769
  40. Rideout T, Harding SV, Jones PJ, Fan MZ. Guar gum and similar soluble fibers in the regulation of cholesterol metabolism: Current understandings and future research priorities. Vasc Health Risk Manag. 2008;4:1023–1033
  41. Keenan JM, Goulson M, Shamliyan T, Knutson N, Kolberg L, Curry L. The effects of concentrated barley beta-glucan on blood lipids in a population of hypercholesterolaemic men and women. Br J Nutr. 2007;97:1162–1168
  42. Khan AR, Khan GY, Mitchel A, Qadeer MA. Effect of guar gum on blood lipids. Am J Clin Nutr. 1981;34:2446–2449
  43. Maki KC, Carson ML, Miller MP, et al. Hydroxypropylmethylcellulose lowers cholesterol in statin-treated men and women with primary hypercholesterolemia. Eur J Clin Nutr. 2009;63:1001–1007
  44. Moreyra AE, Wilson AC, Koraym A. Effect of combining psyllium fiber with simvastatin in lowering cholesterol. Arch Intern Med. 2005;165:1161–1166
  45. Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis. 2006;185:327–330
  46. Bays HE, Goldberg RB. The ‘forgotten’ bile acid sequestrants: is now a good time to remember?. Am J Ther. 2007;14:567–580
  47. Davidson MH. The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opin Pharmacother. 2007;8:2569–2578
  48. Davidson MH, Toth P, Weiss S, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol. 2001;24:467–474
  49. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001;110:352–360
  50. Bays H, Rhyne J, Abby S, Lai YL, Jones M. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin. 2006;22:2191–2200
  51. Insull W. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J. 2006;99:257–273
  52. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008;197:12–24
  53. Kristensen SD, Iversen AM, Schmidt EB. n-3 polyunsaturated fatty acids and coronary thrombosis. Lipids. 2001;36:S79–S82
  54. Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol. 2008;102:429–433
  55. Barter P, Ginsberg HN. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol. 2009;103:435
  56. Robinson JG, Maheshwari N. A “poly-portfolio” for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. Am J Cardiol. 2005;95:373–378
  57. Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis. 2009;202:68–75
  58. Kush D, Hu DY, Ye P, et al. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in asian lipid clinic patients. Cardiology. 2009;114:192–198
  59. Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008;101:1428–1436
  60. Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther. 2008;6:447–470
  61. Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin. 2007;23:2183–2192
  62. Temel RE, Tang W, Ma Y, et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest. 2007;117:1968–1978
  63. Batta AK, Xu G, Bollineni JS, Shefer S, Salen G. Effect of high plant sterol-enriched diet and cholesterol absorption inhibitor, SCH 58235, on plant sterol absorption and plasma concentrations in hypercholesterolemic wild-type Kyoto rats. Metabolism. 2005;54:38–48
  64. Fahey T, Brindle P, Ebrahim S. The polypill and cardiovascular disease. BMJ. 2005;330:1035–1036
  65. Snyder FA. Drug combinations and all cause mortality in heart disease: dosages and types of ACE inhibitors need to be known. BMJ. 2005;331:159
  66. Horwich T. Low-density lipoprotein in the setting of congestive heart failure: is lower really better?. Curr Atheroscler Rep. 2009;11:343–349
  67. Stein EA. After ENHANCE: is more LDL cholesterol lowering even better?. Clin Chem. 2008;54:940–942

PII: S1931-5244(09)00366-1

doi: 10.1016/j.trsl.2009.12.005

Translational Research
Volume 155, Issue 5 , Pages 220-227 , May 2010

Article Tools

* Image Usage & Resolution